<DOC>
	<DOCNO>NCT01541631</DOCNO>
	<brief_summary>In study , hypothesize helminth infection modulate immune response HIV-1 infection result increase HIV-1 multiplication , fast progression AIDS increase episode AIDS-related opportunistic infection . Furthermore , effect helminth infection progression HIV-1 infection dependent helminth infection intensity , host background immunity , nutritional status , demographic factor socio-economic status . Also , treatment helminth infection use praziquantel albendazole among HIV-1 infected individual lead reduction HIV-1 viral load , improvement CD4+ count , CD4+/CD8+ ratio Hb level , improve weight gain reduction episode HIV-1 related opportunistic infection . In addition , HIV-1 infection associate poor anthelminthic treatment outcome compare non-HIV infected individual</brief_summary>
	<brief_title>A Study Co-infections HIV-1 Schistosoma Mansoni Its Impact Praziquantel Treatment Outcomes</brief_title>
	<detailed_description>The propose study main objective investigate epidemiology HIV-1 Schistosoma mansoni co-infections ass association progress HIV positive individual co-infected S. mansoni . The study also assess impact praziquantel treatment S. mansoni related morbidity co-infected HIV positive individual S. mansoni Fishing village , northwest Tanzania . The study design community base intervention trial , consist cross-sectional survey initial baseline survey follow intervention trial . The initial baseline survey include 2000 participant two village . The objective survey determine prevalence HIV-1 infection haemoglobin level . Also , socio-economic , demographic characteristic , individual behaviour relation HIV-1 helminth transmission record . In addition , location altitude household determine use hand-held Garmin GPSmap 60CSX , accuracy ± 5m . After initial survey , study participant group 2 group , one HIV-1 infected group HIV-1 uninfected group . Blood sample examination CD4+ , CD4+/CD8+ HIV-1 viral load obtain HIV-1 positive participant every month period six month . After 6 month prospective longitudinal survey , first follow-up survey recruit study participant conduct objective determine prevalence intensity human intestinal schistosomiasis helminth infection . Other infection also examine , include malaria viral hepatitis . Furthermore , S. mansoni induce morbidity examine use ultrasonography . A blood sample also obtain HIV-1 positive patient , CD4+ , CD4+/CD8+ HIV-1 viral load examine . In survey , individual test HIV-1 negative baseline also screen HIV . After first follow-up survey , three group form , Group A- individual co-infected HIV-1 S. mansoni ( N=270 ) ; Group B- individual infect HIV-1 S. mansoni negative ( N=180 ) Group C- HIV-1 negative S. mansoni positive ( N=1320 ) ( Figure 2 ) . All individual infect S. mansoni helminth detect study irrespective HIV-1 serostatus treat praziquantel ( 40mg/kg ) albendazole ( 400mg ) . At six eight week mass treatment , second survey conduct recruited participant aim determine cure rate S. mansoni chemotherapy praziquantel . The third survey conduct 12 month first follow-up survey aim determine change CD4+ , CD4+/CD8+ , HIV-1 viral load , HIV-1 progression reversibility S. mansoni relate liver morbidity praziquantel</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Opportunistic Infections</mesh_term>
	<mesh_term>Schistosomiasis</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Helminthiasis</mesh_term>
	<mesh_term>Intestinal Diseases , Parasitic</mesh_term>
	<mesh_term>Schistosomiasis mansoni</mesh_term>
	<mesh_term>Albendazole</mesh_term>
	<mesh_term>Praziquantel</mesh_term>
	<criteria>Permanent resident live village 2 year . HIV1 positive individual CD4+ ≥ 400 cells/μl HIV1 positive individual CD4+ &lt; 350 cells/μl , Those antiretroviral therapy ( ARV ) Pregnant woman exclude . Participants chronic disease leukemia , tuberculosis viral hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Human Immunodeficiency Virus-1</keyword>
	<keyword>Schistosoma mansoni</keyword>
	<keyword>Anemia</keyword>
	<keyword>Immune response</keyword>
	<keyword>Opportunistic infection</keyword>
	<keyword>Tanzania</keyword>
</DOC>